A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects

Pfizer

Status and phase: Completed; Phase 1

Conditions: Healthy Subjects

Treatments: Drug: PF-06865571; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT03230383

C2541002

2017-001649-28 (EudraCT Number)

Details and patient eligibility

About

This will be an investigator- and subject-blinded (sponsor open), randomized, placebo controlled, sequential, ascending, multiple oral dose study, with 5 planned cohorts (optional sixth and seventh cohorts). A total of approximately 50 (if 5 cohorts), 60 (if 6 cohorts), and up to 70 (if 7 cohorts) subjects will be randomized in this study. Subjects in each cohort will be randomized to receive PF-06865571 or matching placebo with approximately 10 subjects dosed in each cohort.

For a given subject in any cohort, the total study duration from screening to follow-up phone call will be between approximately 7 to 11 weeks.

Enrollment: 60 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy males and female of non-childbearing potential;
• Age of 18-55, inclusive;
• Body Mass Index 22.5 to 35.4 kg/m2, inclusive;
• Body weight greater than 50 kg;
• Not on any prescription or non-prescription drugs within 7 days or 5 half-lives prior to first dose.

Exclusion criteria

• Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergises, but excluding untreated, asymptomatic, seasonal allergies at time of dosing);
• Subjects with fasting LDL-C level >190 mg/dL following an overnight fast of at least 10 hours, at the Screening visit, confirmed by a single repeat, if deemed necessary.
• Subjects with fasting TG level >400 mg/dL following an overnight fast of at least 10 hours, at the Screening visit, confirmed by a single repeat, if deemed necessary.
• Any condition possibly affecting drug absorption (eg, gastrectomy).
• A positive urine drug test.
• History of regular alcohol consumption exceeding 7 drinks/week for female subjects or 14 drinks/week for male subjects (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months before screening.
• Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of investigational product (whichever is longer).
• Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day or 2 chews of tobacco per day.
• Pregnant female subjects; breastfeeding female subjects; male subjects with partners currently pregnant; fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product.
• Unwilling or unable to comply with the criteria in the Lifestyle Requirements section of this protocol.
• Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Double Blind

---

60 participants in 7 patient groups

Cohort 1_90mg and Matching Placebo

Experimental group

Treatment:

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Drug: Placebo

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Cohort 2_300mg and Matching Placebo

Experimental group

Treatment:

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Drug: Placebo

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Cohort 3_900mg and Matching Placebo

Experimental group

Treatment:

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Drug: Placebo

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Cohort 4_1800mg and Matching Placebo

Experimental group

Treatment:

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Drug: Placebo

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Cohort 5_3000mg and Matching Placebo

Experimental group

Treatment:

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Drug: Placebo

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Optional Cohort 6_TBD mg and Matching Placebo

Experimental group

Treatment:

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Drug: Placebo

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Optional Cohort 7_TBD mg and Matching Placebo

Experimental group

Treatment:

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571

Drug: Placebo

Drug: PF-06865571

Drug: PF-06865571

Drug: PF-06865571